L

Lavipharm SA
XBER:BXA

Watchlist Manager
Lavipharm SA
XBER:BXA
Watchlist
Price: 0.468 EUR 1.3%
Market Cap: €23.9m

Net Margin

7.2%
Current
Declining
by 0.2%
vs 3-y average of 7.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
7.2%
=
Net Income
€3.9m
/
Revenue
€53.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
7.2%
=
Net Income
€3.9m
/
Revenue
€53.3m

Peer Comparison

Country Company Market Cap Net
Margin
GR
Lavipharm SA
ATHEX:LAVI
207.8m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

In line with most companies in Greece
Percentile
45th
Based on 369 companies
45th percentile
7.2%
Low
-10 460.4% — 1.9%
Typical Range
1.9% — 20.4%
High
20.4% — 3 030.4%
Distribution Statistics
Greece
Min -10 460.4%
30th Percentile 1.9%
Median 8.6%
70th Percentile 20.4%
Max 3 030.4%

Lavipharm SA
Glance View

Market Cap
23.9m EUR
Industry
Pharmaceuticals

Lavipharm SA engages in the manufacture and import of pharmaceuticals and veterinary products. The company is headquartered in Athina, Attiki. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. The company is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

BXA Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
7.2%
=
Net Income
€3.9m
/
Revenue
€53.3m
What is Lavipharm SA's current Net Margin?

The current Net Margin for Lavipharm SA is 7.2%, which is below its 3-year median of 7.4%.

How has Net Margin changed over time?

Over the last 3 years, Lavipharm SA’s Net Margin has increased from 2.5% to 7.2%. During this period, it reached a low of 1.8% on Dec 31, 2022 and a high of 17% on Dec 31, 2024.

Back to Top